


In the Claims:

Claims 1 to 34 (cancelled).


Claim 35 (currently amended)

A compound of the formula




(I)G

in racemic, enantiomeric form or any combination of these forms, in which Het is a heterocycle with 5 members ~~comprising~~ consisting of 2 heteroatoms and such that formula (I)G corresponds exclusively to one of the following sub-formulae is:



; or


(I)G1



(I)G2

in which

A is



radical in which Q is $-\text{OR}^{22}$ and R²² is hydrogen and R¹⁹, R²⁰ and R²¹ are hydrogen or alkyl or alkyl,

X is $-\text{S}-$,

R¹ and R² are hydrogen,

B is hydrogen,

Ω is $\text{NR}^{46}\text{R}^{47}$,

R⁴⁶ and R⁴⁷ are hydrogen ~~or alkyl~~;

n, each time that they occur, is independently an integer from 0 to 6;

and its pharmaceutically acceptable salts.

Cancel Claim 36.

Claim 37 (previously presented) The compound of claim 35 or its salt, wherein n is an integer from 0 to 2.

Claim 38 (currently amended) The compound of claim 37 or its salt, wherein n is 1 R₁ and R₂ are hydrogen.

Claim 39 (currently amended) The compound of claim 37 or its salt, wherein n is 1 R₁ is hydrogen and R₂ is alkyl.

Cancel Claim 40.

Claim 41 (currently amended) A pharmaceutical composition containing, comprising as active principle, a compound of general formula (I)_G as defined in claim 35, or a pharmaceutically acceptable compound of such a compound, and at least one pharmaceutically acceptable excipient.

Cancel **Claim 42**.

Claim 43 (currently amended) The pharmaceutical composition of claim 18 41 wherein the active principle is butyl 2-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl) ethylcarbamate or one of its pharmaceutically acceptable salts.

Claim 44 (cancelled).

Cancel **Claims 45 to 48**.

Add the following claim:

Claim 49 (new) A compound of claim 35 wherein n is 0.